

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

TYRIAN DIAGNOSTICS LIMITED

ABN

56 080 277 998

Quarter ended ("current quarter")

30 JUNE 2012

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (12 months) \$A'000
1.1	Receipts from customers	325	752
1.2	Payments for (a) staff costs	-	(1,918)
	(b) advertising and marketing	-	(83)
	(c) research and development	(10)	(185)
	(d) leased assets	-	-
	(e) other working capital	(209)	(1,026)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	7	82
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid (R&D tax offset refund received)	-	207
1.7	Other (Forex effects on cash & cash equiv.)	-	-
Net operating cash flows		113	(2,171)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (₁₂ months) \$A'000
1.8 Net operating cash flows (carried forward)	113	(2,171)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	85
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	85
1.14 Total operating and investing cash flows	113	(2,086)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.		
1.16 Proceeds from sale of forfeited shares		
1.17 Proceeds from borrowings		
1.18 Repayment of borrowings		
1.19 Dividends paid		
1.20 Other (costs of capital raising activities)		
Net financing cash flows	-	-
Net increase (decrease) in cash held	113	(2,086)
1.21 Cash at beginning of quarter/year to date	959	3,158
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	1,072	1,072

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	33
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions 	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	N/A	N/A
3.2 Credit standby arrangements	N/A	N/A

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash


Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	1,072	959
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (Term Deposits)	-	-
Total: cash at end of quarter (item 1.23)		1,072	959

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity		Eukarion Inc.
5.2	Place of incorporation or registration		Delaware, USA
5.3	Consideration for acquisition or disposal		\$USD 1,000 applied as offset and in settlement of creditor.
5.4	Total net assets		\$nil
5.5	Nature of business		Maintenance of patent portfolio

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does ~~/does not~~* (delete one) give a true and fair view of the matters disclosed.



Sign here: Date: ..30 July 2012....
 (Director/Company secretary)

Print name: Andrew Blunden.....

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.